

Innovative cancer therapies that target specific genes and proteins to slow or prevent carcinogenesis and tumor proliferation are being increasingly used in clinical practice.
These targeted therapies have been included in standard of care (SoC) in many markets for various indications in which they have shown to offer a clear benefit to patients over standard chemotherapies. The evolving SoC is monitored by payer bodies and as a result, they have adopted targeted therapies as appropriate comparators in cancer health technology assessments (HTAs).